Leukocyte Recovery and Early Treatment-Related Mortality After Bone Marrow Transplantation

To the Editor:

In a study of considerable practical relevance, Offner et al. have shown that from 15 days after autologous or allogeneic bone marrow transplantation (BMT), the risk of mortality due to any cause within the first 100 days becomes progressively greater in patients whose absolute neutrophil count is \( <0.1 \times 10^9/L \). This observation could be of clinical significance in the third and fourth week after transplantation, when additional therapeutic interventions may be applied to patients with neutrophil counts of \( <0.1 \times 10^9/L \) to decrease early mortality.

There are some limitations to the study: although the investigators mention that causes of death such as relapse and regimen-related toxicity could diminish the relative importance of the degree of neutropenia in autograft recipients, these causes of death as well as fatal acute graft-versus-host disease (GVHD), which account for a significant number of deaths in the first 100 days after allogeneic BMT, could decrease the impact of neutropenia after allogeneic transplantation as well. Secondly, although neutropenia is the most important risk factor for death due to bacterial or fungal infections, the use of the absolute neutrophil count may ignore the contribution of monocytes to recovery from infections. Also, in our experience, the absolute neutrophil count is somewhat unreliable and prone to considerable variation when the total leukocyte count is low.

Because there is no universally accepted definition of delayed engraftment after BMT, and prolongation of pancytopenia is associated with an increasing probability of serious infections and bleeding, we have tried to arrive at an operational definition of graft failure after allogeneic BMT. To specifically identify patients who could benefit from early intervention in the third week posttransplant, we limited the events studied to (1) death primarily as a result of infection, hemorrhage, or graft failure within 3 months; and (2) second infusion of allogeneic or autologous marrow as therapy for primary failure of engraftment within 2 months of the first infusion. Primary failure of engraftment was usually diagnosed on the basis of an absolute neutrophil count of \( <0.1 \times 10^9/L \) on day 21 with a markedly hypocellular marrow. Detailed information on the mode of death, disease status at death, and principal and contributory causes of death was extracted from a prospective database to ensure the exclusion of patients dying of infections or hemorrhage secondary to acute GVHD because the latter were classified as dying primarily of GVHD.

Serial total leukocyte counts obtained by automated counters on absolute neutrophil count is \( \geq 1 \times 10^9/L \). This observation could be of clinical significance in the third and fourth week after transplantation, when additional therapeutic interventions may be applied to patients with neutrophil counts of \( <0.1 \times 10^9/L \) to decrease early mortality.

Figures 1 and 2 show the high significance. In multivariate analysis, a leukocyte count \( \leq 0.2 \times 10^9/L \) on day 16 was the strongest factor predicting subsequent death (25 of 114 patients \( v \) 23 of 546 patients with leukocytes \( >0.2 \times 10^9/L \), relative risk 4.5, \( P < .0001 \)) and death/second infusion (48 of 114 \( v \) 47 of 546, relative risk 5.5, \( P < .0001 \)). The findings were similar in recipients of non-T-cell depleted marrow from HLA-identical siblings (relative risks 4.5 and 7.6, \( P = .0001 \) and <.0001), and after substitution of the day 16 leukocyte counts with day 14 and day 17; with the leukocyte count being the strongest factor in all analyses.

---

**Fig 1. The probability of death:** Statistical significance by day after transplant. A chi square value of 3.85 corresponds to a \( P \) value of .05.
Although our findings are similar to those of Offner et al, by specifically defining deaths that may be directly attributable to low counts, we have highlighted the importance of early leukocyte recovery after allogeneic BMT. Therefore, we believe that “graft failure” should be defined operationally as early as 2 weeks after BMT when patients are well and more likely to benefit from any intervention rather than at day 21 or day 28 when patients may be too unwell. On the basis of this, an algorithm can be evolved to limit the use of growth factors to patients most likely to benefit from them, to salvage patients at risk of complications of low counts early before their clinical condition deteriorates, and to design studies of growth factors. We suggest that patients with leukocyte counts of $0.2 \times 10^9/L$ or less 14-16 days after BMT should be started on G-CSF or GM-CSF even if they are clinically well, and consideration should be given for a further infusion of cells, especially if the risk of graft failure is high as in unrelated or mismatched transplants.

Jayesh Mehta
Ray Powles
Clive Horton
Jennifer Treleaven
Seema Singhal
Leukaemia Unit
Royal Marsden Hospital
Surrey, UK

REFERENCES

DAMI Cell Line

To the Editor:

It has come to our attention that samples of the DAMI cell line originally deposited by us in the American Type Culture Collection (ATCC) and subsequently distributed to members of the scientific community may share some unique genetic markers with the HEL cell line. We do not know the significance of this finding nor do we know how the changes arose and are working closely with the ATCC to resolve the problem. We remain convinced that the original DAMI line reported in Blood 72:1968, 1988 had unique cytogenetic and phenotypic features. We wish only to alert our colleagues that a change may have occurred in what we identified as the DAMI line since submission of the original manuscript. Thus, investigators should use caution when interpreting any unique results obtained with the DAMI line.

Robert I. Handin, MD
Brigham and Women’s Hospital
Hematology-Oncology Division
Boston, MA
Leukocyte Recovery and Early Treatment-Related Mortality After Bone Marrow Transplantation

Jayesh Mehta, Ray Powles, Clive Horton, Jennifer Treleaven and Seema Singhal